A stealth biotechnology company that has attracted curiosity and speculation because of its eminent co-founders emerged into the spotlight on Thursday with the announcement of its first scientific discovery — a CRISPR-associated enzyme that promises several advantages over other ones — and an explanation of where it hopes to find scientific riches.

Arbor Biotechnologies, said co-founder David Walt of Brigham and Women’s Hospital and Harvard, wants to scour the microbial world — “this uncharted region,” he calls it — in search of molecules “that will benefit humans in health, agriculture, and the environment.” The startup is premised on the idea that “microbes have developed an incredible diversity of chemical and biochemical solutions to the myriad environmental challenges they encounter,” he told STAT.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy